4th Microbiome Movement - Drug Development Summit Europe 2020

4th Microbiome Movement - Drug Development Summit Europe is organized by Hanson Wade and will be held from Feb 04 - 06, 2020 at The Tower Hotel, London, England, United Kingdom.

Main Conference: Feb 05 - 06, 2020
Pre-conference Workshop: Feb 04, 2020

Description:
Part of the foremost conference series for microbiome researchers in industry, the 4th Microbiome Movement – Drug Development Europe 2020 returns to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.

Across three days of case-studies, discussion and debates, learn how industry and academic leaders are understanding microbiome functionality across key therapeutic modalities, leveraging big data platforms to deduce causality, and overcoming regulatory, clinical and manufacturing hurdles to further accelerate their pipeline across new disease targets.

At this critical time, and as the microbiome community waits for the first clinical breakthrough, join your peers and unlock the potential of the human microbiome to create the next generation of microbiome-based therapeutics and diagnostic candidates of the future.

Pre-conference Workshops:
Workshop A: Treating Women's Health through the Human Microbiome
Time: 11:30-14:00
Description: With most of the research attention on the gut microbiome, there is a growing interest in the microbiome to better understand female reproductive, vaginal, and offspring health. More specifically, recent evidence has demonstrated that the vaginal microbiome plays an important role in successful fertilisation and health pregnancies. This workshop will review the current understanding of microbes in female health, as well as the opportunity to develop new microbiome-targeted products for diseases including HPV infections, bacterial vaginosis as well as pregnancy health.

Join this session to:
• Better identify how techniques are applied to determine a “healthy” vaginal microbiome
• Understand how the composition of the microbiome change for pregnant and postpartum women?
• Identify which health conditions can be better understood through analysis of the vaginal, oral and gut microbiome of women?
• Develop new microbiome-targeting products that help tackle widespread needs in women’s health

Workshop B: Using Metagenomics and the Human Microbiome to Address Antimicrobial Resistance
Time: 14:30-17:00
Description: As the spread of infectious diseases and growing AMR continues within the hospital environment, information gathered from the microbiome, metagenomics, and bioinformatic analysis has been identified as a tool to help diagnose infections and stop the spread of infectious disease. This workshop will outline the tools required to create efficient microbiome systems that can help identify AMR pathogens, manage hospital systems, and protect humans against infectious disease.

Join this session to:
• Harness microbial information to understand how microbes evolve and spread in various environments, including hospitals
• Understand how new bioinformatics tools can be used to provide new insights on AMR pathogens
• Learn how artificial intelligence can better predict patterns to guide patient treatments
• Leverage insights gathered from the microbiome to fight infectious disease through the development of precision diagnostics

Workshop C: Learning from FMT to Inform Clinical
Time: 15:00 - 17:30
Description: Trial Development of Microbiomebased Therapeutics Often seen as the origin of microbiome-targeting therapies, FMT can provide important insights to drug developers and healthcare practitioners on the clinical efficacy of bacteria-based therapeutics to help treat disease. This workshop will gather insights from clinical experts to discuss the important milestones of FMT as a therapeutic modality and understand how these insights can be leveraged to design more targeted microbiomebased therapeutics.

Join this session to:
• Gain an update on the current use of FMT as a modality to treat disease
• Understand the successes and challenges of using FMT in practice
• Learn how results from FMT interventions can help the drug development community learn the key clinical trial considerations for future microbiome-targeting therapies
• Develop standards in clinical microbiome intervention studies to better assess comparability of results 

Additional details will be posted as soon as information is available.